DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

This publication has 46 references indexed in Scilit:

• Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
  2002
• Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
  2001
• Established Clinical Use of Octreotide and Lanreotide in Oncology
  Chemotherapy, 2001
• RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors
  Journal of Clinical Endocrinology & Metabolism, 2000
• DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy1
  Endocrinology, 1999
• ^99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals
  Chemical Reviews, 1999
• Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• The somatostatin receptor-targeted radiotherapeutic [ 90 Y-DOTA- d Phe 1 ,Tyr 3 ]octreotide ( 90 Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.
  1995
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
  European Journal of Nuclear Medicine and Molecular Imaging, 1993